肝细胞癌血管生成调控与抗血管治疗进展被引量：3

Angiogenesis regulation and anti-angiogenesis therapy of hepatocellular carcinoma

导出

摘要肝细胞癌（HCC）的血管生成受血管生成因子与血管生成抑制因子的调控。血管生成抑制剂治疗HCC可抑制癌的生长与转移,试验性治疗应用已显示出一定效性。 The angiogenesis of hepatocellular carcinoma is regulated by a species of angiogenic factors and angiogenesis inhibitors. Anti-angiogenic drugs can inhibit carcinoma growth and metastasis, experimental therapy has showed some positive effects.

作者鲁光平（综述）于志坚（审校）

机构地区南通大学附属医院肿瘤中心

出处《国际肿瘤学杂志》 CAS 2007年第8期605-608,共4页 Journal of International Oncology

关键词癌肝细胞血管生成诱导剂血管生成抑制剂治疗应用 Carcinoma,hepatocellular Angiogenesis inducing agents Angiogenesis inhibitor Therapeutic uses

分类号 R730.53 [医药卫生—肿瘤] R735.7 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1Tsang-EnWang,Chin-RoaKao,$hee-ChanLin,Wen-HsiungChang,Cheng-Hsinchu,JohsonLin,Ruey-KuenHsieh.Salvage therapy for hepatocellular carcinoma with thalidomide[J].World Journal of Gastroenterology,2004,10(5):649-653. 被引量：15
2Geng-WenHuang Lian-YueYang Wei-QunLu.Expression of hypoxia-inducible factor la and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival[J].World Journal of Gastroenterology,2005,11(11):1705-1708. 被引量：51
3赵建军,胡敬群,蔡建强,杨晓洁,杨治华.Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma[J].Chinese Medical Journal,2003(5):772-776. 被引量：49
4Zhi-Jian Yu,Jia-Wei Yu,Wei Cai,Hong-Xin Yuan,Xiao-Yan Li,Ye Yuan,Jian-Ping Chen,Xiao-Yin Wu,Deng-Fu Yao.Evaluation of HCPTd_1, d_(14)-double passaged intervening chemotherapy protocol for hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(33):5221-5225. 被引量：14
5赵明,吴沛宏,曾益新,夏建川,张福君,冼励坚,张毓平,周琨,范卫君,张亮,高飞,周启明.经肝动脉栓塞化疗序贯联合射频消融和细胞因子诱导的杀伤细胞治疗肝细胞癌的随机研究[J].中华医学杂志,2006,86(26):1823-1828. 被引量：53
6Overexpression of TIMP-1 mediated by recombinant adenovirus in hepatocellular carcinoma cells inhibits proliferation and invasion in vitro[J].Hepatobiliary & Pancreatic Diseases International,2006,5(3):409-415. 被引量：6
7Zhi-Zhen Dong,Deng-Fu Yao,Deng-Bing Yao,Xin-Hua Wu,Wei Wu,Li-Wei Qiu,Dao-Rong Jiang,Jian-Hua Zhu,Xian-Yong Meng.Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(30):4655-4660. 被引量：45

二级参考文献18

1Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量：214
2Bing-Hui Yang, Jing-Lin Xia, Li-Wen Huang, Zhao-You Tang, Ming-Shan Chen, Jin-Qing Li, An-Min Liang, Qin-Guo Mo, Hui-Shan Lu, Chao-Liu Dai, Lu-Nan Yan, Zhi-Jian Yu, Rong-Sheng Rao, Le-Qun Li, Zhi-Xiong Su, Zhuang-Wei Fang Shanghai, China Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai 200032, China,Tumor Hospital, Zhongshan University, Guangzhou 510000, China Tumor Hospital, Guangxi Medical Universi- ty, Nanning 530000, China,Xiehe Hospital, Fujian Medical University, Fuzhou 350000, China,Second Hos- pital, Chinese Medical University, Shenyang 110000, China ,Huaxi Hospital, Sichuan University, Chengdu 610041, China ,Hospital Affiliated to Nantong Medical University, Nantong 226000 , China,Second Hospital, Jiangxi Medical University, Nanchang 330000 , China ,First Hospital Affiliated to Guangxi Medical University, Nanning 530000 , China ,People’s Hospital of Hainan Province, Haikou 570000, China.Changed clinical aspects of primary liver cancer in China during the past 30 years[J].Hepatobiliary & Pancreatic Diseases International,2004,3(2):194-198. 被引量：20
3施明,张冰,汤紫荣,雷周云,王慧芬,冯永毅,刘敬超,范振平,李捍卫,牟劲松,王福生.肝癌患者自体细胞因子诱导杀伤细胞治疗后免疫活性细胞的检测及其临床意义[J].中华医学杂志,2003,83(23):2049-2053. 被引量：37
4杨薇,陈敏华.射频消融治疗肝肿瘤疗效及其影响因素[J].中华医学杂志,2005,85(5):354-357. 被引量：13
5于志坚,孟宪镛,成建萍,刘艳华,郑毓荃,黄介飞,吴建新,吴晓音.THAE、TSAI、PVE序贯治疗伴门静脉癌栓晚期肝癌的临床研究[J].中华消化杂志,1996,16(S1):37-40. 被引量：4
6姚登福,董志珍,杨大明,朱云松,蒋道荣,陆建新.外周血甲胎球蛋白mRNA扩增在肝癌诊断和鉴别诊断中的价值[J].中华普通外科杂志,2000,15(8):474-477. 被引量：8
7杨秉辉,夏景林.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324-324. 被引量：1012
8管忠震.羟基喜树碱需进一步规范化临床研究[J].癌症,2001,20(12):1333-1334. 被引量：9
9张力,李苏,廖海,姜文奇,管忠震.羟基喜树碱Ⅰ期药代动力学及人体耐受性临床研究[J].癌症,2001,20(12):1391-1395. 被引量：81
10Lun-Xiu Qin Zhao-You Tang,Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai,China.The prognostic molecular markers in hepatocellular carcinoma[J].World Journal of Gastroenterology,2002,8(3):385-392. 被引量：163

共引文献220

1陆园园,姚登福,吴信华,黄华,邱历伟,吴玮.肝癌及癌旁组织IGF-Ⅰ受体表达及临床病理学特征[J].南通大学学报（医学版）,2008,28(3):169-171. 被引量：11
2吴付兵,李积德.反应停在实体肿瘤治疗中的应用[J].中国医药指南,2008,6(22):90-94.
3于燕霞,石远凯.沙利度胺在恶性肿瘤治疗中的应用[J].癌症进展,2005,3(4):353-359. 被引量：14
4Luigi Rossi,Federica Zoratto,Anselmo Papa,Francesca Iodice,Marina Minozzi,Luigi Frati,Silverio Tomao.Current approach in the treatment of hepatocellular carcinoma[J].World Journal of Gastrointestinal Oncology,2010,2(9):348-359. 被引量：11
5Deng-Fu Yao,Hua Jiang,Min Yao,Yue-Ming Li,Wen-Jing Gu,Yu-Cheng Shen, Li-Wei Qiu,Wei Wu,Xin-Hua Wu and Wen-Li Sai Research Center of Clinical Molecular Biology,Department of Laboratory Science,and Department of Oncology,Affiliated Hospital of Nantong University,Nantong 226001, China,Third Department of Medicine,Jiaonan People’s Hospital,Jiaonan 266400,China.Quantitative analysis of hepatic hypoxia-inducible factor-1α and its abnormal gene expression during the formation of hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2009,8(4):407-413. 被引量：28
6Zhi-Zhen Dong,Deng-Fu Yao,Min Yao,Li-Wei Qiu,Lei Zong,Wei Wu, Xin-Hua Wu,Deng-Bing Yao and Xian-Yong Meng Department of Diagnostics,Research Center of Clinical Molecular Biology,Department of Laboratory Science,and Department of GastroenterologyAffiliated Hospital,and Institute of Neurosciences,Nantong University,Nantong 226001,China.Clinical impact of plasma TGF-β1 and circulating TGF-β1 mRNA in diagnosis of hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2008,7(3):288-295. 被引量：27
7Abnormal expression of insulin-like growth factor-Ⅱ and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development[J].Hepatobiliary & Pancreatic Diseases International,2008,7(4):406-411. 被引量：16
8Yao, Deng-Fu,Dong, Zhi-Zhen,Yao, Min.Specific molecular markers in hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2007,6(3):241-247. 被引量：55
9任洪军,张全安,赵伟.血管内皮生长因子及其受体与肝癌治疗的研究进展[J].肿瘤研究与临床,2008,20(1):70-72. 被引量：8
10Mónica Enguita-Germán,Puri Fortes.Targeting the insulin-like growth factor pathway in hepatocellular carcinoma[J].World Journal of Hepatology,2014,6(10):716-737. 被引量：11

同被引文献32

1Luigi Rossi,Federica Zoratto,Anselmo Papa,Francesca Iodice,Marina Minozzi,Luigi Frati,Silverio Tomao.Current approach in the treatment of hepatocellular carcinoma[J].World Journal of Gastrointestinal Oncology,2010,2(9):348-359. 被引量：11
2刘连新,朱安龙,陈炜,郭化鑫,王秀琴,刘芝华,张亭栋,姜洪池,吴旻.三氧化二砷对原发性肝癌的作用及其机理研究[J].中华外科杂志,2005,43(1):33-36. 被引量：94
3郝明志,林海澜,陈强,吴晖,余文昌,陈唐庚.沙利度胺联合肝动脉栓塞化疗治疗原发性肝癌随机对照研究[J].癌症,2007,26(8):861-865. 被引量：32
4Dai CX, Gao Q, Qiu sJ, et al. Hypoxia - inducible factor - 1 alpha, in association with inflammation, angiogenesis and MYC, is a criii- cal prognostic factor in patients with HCC after surgery [ J ]. BMC Cancer,2009,9:418.
5Llovet JM,Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepa- tocellular carcinoma[J]. N Engl J Med,2008,359(4) :378 -390.
6Yao DF, Qiu LW, Wu W, et al. Dynamic alterations of VEGF and intervention of its expression on effect of hepatocyte malignant transformation [ J ]. Zhonghua Yi Xue Za Zhi, 201 O, 90 ( 42 ) : 3014 -3018.
7Shao YY, Lin ZZ, Hsu C, et al. Early alpha -fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in pa- tients with advanced hepatocellular carcinoma [ J ]. Cancer, 2010, 116(19) :4590 -4596.
8Lencioni R. Loco - regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies [ J ]. Oncology, 2010,78 ( Suppl 1 ) : 107 - 112.
9Pinter M, Wichlas M, Schmid K, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach : a phase Ⅰ/Ⅱ thai[ J]. Eur J Gastroenterol Hepato1,2008,20(10) : 1012 - 1019.
10Yau T, Chart P, Wong H, et al. Efficacy and tolcrability of low- dose thalidomide as first - line systemic treatment of patients with advanced hepatocellular carcinoma[ J ]. Oncology ,2007,72 ( Suppl 1 ) :67 - 71.

引证文献3

1鲁光平,潘骥群,邵柏,于志坚.肝细胞癌分子靶向治疗现况与展望[J].现代肿瘤医学,2013,21(1):208-212. 被引量：6
2潘骥群,鲁光平,邵柏,徐炳山,陆晓梅,于志坚.肝动脉化疗栓塞序贯沙利度胺靶向治疗中晚期肝癌近期疗效观察[J].现代肿瘤医学,2013,21(4):811-813. 被引量：10
3鲁光平,常仁安,刘春,于志坚,巫荣华,黄华.沙利度胺联合三氧化二砷腹腔注射对肝癌细胞SMMC7721移植瘤生长的影响及机制[J].山东医药,2013,53(27):29-32. 被引量：6

二级引证文献22

1张昊,丛庆学.肝癌的靶向治疗[J].医学信息（医学与计算机应用）,2014,0(19):639-639.
2吴晔,王震侠.肝细胞癌血管生成及抗血管生成治疗的研究进展[J].肝胆胰外科杂志,2014,26(1):78-82. 被引量：4
3沈茜,周益龙,邵冰峰,田思源,徐爱兵.索拉非尼对中晚期肝细胞癌患者的影响[J].现代肿瘤医学,2014,22(6):1378-1380. 被引量：1
4张霞,鲁光平,潘骥群.沙利度胺联合局部放疗及唑来膦酸治疗原发性肝癌骨转移近期疗效观察[J].山东医药,2014,54(13):38-39. 被引量：10
5黄炽明,符以恒,杜嘉林,刘全芳,黄毅捷,陈政波.国内沙利度胺联合肝动脉化疗栓塞治疗原发性肝癌的Meta分析[J].中华临床医师杂志（电子版）,2014,8(14):111-116. 被引量：4
6田宇楠,祝慧凤,万东.肝肺肿瘤临床联合用药的研究进展[J].实用临床医药杂志,2014,18(11):191-194. 被引量：4
7彭佩纯,陈然,文彬,邓鑫.索拉非尼治疗晚期原发性肝癌有效性和安全性的系统评价[J].中国全科医学,2014,17(28):3368-3374. 被引量：8
8孙晓.吉西他滨联合奥沙利铂经肝动脉化疗栓塞治疗中晚期肝癌的临床疗效分析[J].中国实用医药,2015,10(1):108-109. 被引量：3
9朱艳,柏根基.扩散加权成像联合甲胎蛋白在肝癌术后疗效评价中的研究进展[J].医学综述,2015,21(4):629-631. 被引量：2
10陈子瑶,梁健,邓鑫.沙利度胺联合TACE治疗原发性肝癌疗效与安全性的系统评价[J].世界华人消化杂志,2015,23(2):291-307. 被引量：14

1王红梅,刘晓明.血管新生的机制及在皮肤肿瘤和银屑病中的作用[J].国外医学（皮肤性病学分册）,2005,31(6):361-363. 被引量：4
2姚军萍(综述),汪兴洪(审校).缺氧诱导因子-1与多发性骨髓瘤[J].白血病．淋巴瘤,2009,18(9):574-576.
3罗波,孙立江.膀胱移行细胞癌组织VEGF和COX-2表达及意义[J].青岛大学医学院学报,2009,45(1):29-31. 被引量：5
4刘涛,任精华,伍钢.卵泡刺激素与肿瘤血管生成[J].国际肿瘤学杂志,2011,38(8):572-574. 被引量：3
5钟世顺,张振书.大肠癌血管生成及p53基因对其调控作用的研究[J].胃肠病学,2001,6(C00):85-86.
6杨素梅,刘可玲,王立敏,高建宏,李华,高玉霞.青蒿琥酯对人卵巢癌细胞诱导血管新生的抑制效应[J].河北医药,2011,33(13):1949-1951. 被引量：2
7闫长青,赵玉沛.血管生成因子VEGF、bFGF、endostatin在胰腺癌细胞中的表达[J].中华外科杂志,2009,47(10):787-790. 被引量：8
8刘淳,杨蕴,刘双静,李雅钗.子宫内膜癌中ER、PR、MK、VEGF的表达及与病理特征的关系[J].河北医药,2010,32(11):1364-1366. 被引量：6
9王彦敏.血管生成因子VEGF研究进展[J].河北医药,2010,32(11):1456-1458. 被引量：32
10张则伟,赵彩芳.胰腺癌的抗血管生成治疗研究进展[J].浙江医学,2008,30(1):94-97. 被引量：2

国际肿瘤学杂志

2007年第8期

浏览历史

内容加载中请稍等...

肝细胞癌血管生成调控与抗血管治疗进展被引量：3

参考文献7

二级参考文献18

共引文献220

同被引文献32

引证文献3

二级引证文献22

相关作者

相关机构

相关主题

浏览历史

肝细胞癌血管生成调控与抗血管治疗进展 被引量：3

参考文献7

二级参考文献18

共引文献220

同被引文献32

引证文献3

二级引证文献22

相关作者

相关机构

相关主题

浏览历史

肝细胞癌血管生成调控与抗血管治疗进展被引量：3